Hi, here is a nice and very helpful discussion in RG that may help you. Yours is for sure a tricky question, since the presence of a strong and reliable diagnostic/prognostic circulating marker is still much debated among scientists all over the world. Overall, it seems that the S100B protein would be a reliable serum marker for monitoring patients with malignant melanoma (see attached paper). Good luck!

https://www.researchgate.net/post/Name_of_the_tumor_marker_for_malignant_melanoma_specific_for_Serum_and_Tissues

https://www.ncbi.nlm.nih.gov/pubmed/24312329

Dear Riva,

I do not think that you need "complicated blood monitoring" for this model.

At the 10th day post B16F10 cell injection, you will have a lot of metastases easily detectable in the lungs because high levels of melanin expression (see the attached articles by Mathieu et al.). At the 15th, you will have about 50 / 50% of metastatic versus lung tissues.

If you want to monitor a blood marker, as said by Damiano, you can use S100B.

You can also try to use galectin-1, whch is highly expressed in the B16F10 model (see the Mathieu et al., articles). We did it for patients, but not for mice (see Verschuere et al., and Saussez et al.).

Best regards

Robert

Sorry Riva,

The article I attached for Saussez et al. is not the right one!

Here it is!

Best regards

Robert

Dear Robert and Domiano,

Thanks so much for your helpful response! I've narrowed down to S100B, Galectin-1 and MLANA gene for now, although I think Galectin-1 would be expressed in non-treated controls as well, hopefully there would be a difference in intensity. Still searching for some serum markers that can be studied in the context of lung cancer. 

Best Regards,

Riva